


The monoclonal antibody Itolizumab received authorization to start a phase III clinical trial in Covid-19 patients in the US, Mexico and Brazil, reported on Wednesday Cuba's Center for Molecular Immunology (CIM).
Read more Cuba's medicine will be tested in the US, Mexico and Brazil
Page 390 of 500